GGF2: Phase I started

Acorda began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial evaluating IV GGF2 in about 50 patients. Acorda gained rights to GGF2 from CeNes Pharmaceuticals plc, which was acq...